Updated 08:09 GMT, 16 Nov 2026 SPX 7,561.67 -0.40% NDX 27,943.74 -1.22% VIX 19.30 +3.21% GOLD 3,859.70 -0.68% CL 88.67 +0.12% BTC 64,634.95 -1.03%
NAS100 27,944 −1.22% S&P 7,562 −0.40% GOLD $3,860 −0.68% BTC $64,635 −1.03% VIX 19.30 +3.21% latest tape · as of 08:09 UTC
The Screen · Basic Materials · Other Industrial Metals & Mining

Atlas Lithium Corp

ATLX · NASDAQ · USD · Market cap $57M · 64 employees

Atlas Lithium Corporation operates as a mineral exploration and development company in Brazil.

FAIL · Does not pass the screen
1.54 USD

Price as of 13 Nov 2026Daily close, not a live quote

Screened 2026-11-13 · the tape above runs as of 08:09 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price1.54 USD at the 13 Nov 2026 close
  • Our regime readMarkdown, as of 15 Nov 2026
  • Ethical screenDoes not pass
  • OptionsOpen interest leans slightly to calls (put/call 0.71)
  • Last reviewed13 Nov 2026 (3 days ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: range not available (screen dated 2026-11-13).

Current read
Markdown ?
Screened · screened 2026-11-13
  • Trend Markdown
  • Insiders no filings inside 60 days, left as found
  • Positioning no disclosures inside 60 days, left as found
  • Options no verdict drawn today, left as found
  • Ethical does not pass the values gate
Price1.54 USD
Ethical score70.0/100
Our investment reviews on this name
2026-09-24Read Markdown2.94-47.6% to today ✓Accumulation gives way to Markdown after a 7% slide in 5 weeks
2026-08-22Read Accumulation3.15-51.1% to today Distribution gives way to Accumulation after a 16% slide in 7 weeks
2026-07-02Read Distribution3.73-58.7% to today ✓First review on file: Distribution

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its markdown label.

Atlas Lithium Corp holds its Markdown at $1.54. Elevated stress, defensive posture warranted, held for 253 days.

As held on the ledger · 2026-11-13
PhaseMarkdown · caution
Quantitative stateElevated stress, defensive posture warranted, held for 253 days
Price at the screen$1.54
ValuationN/A trailing · -3.11 forward price to earnings
Values screenFAIL · score 70.0
Beta0.19
The Workings

Five Screens, Shown in Full

Does not pass. Interest/revenue 57.3%

TestFigureLimitWhat it meansStatus
Business activity Permissible Core business clean Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. Pass
Debt load 12.10% Below 33% Interest-bearing debt is just 12.1% of its assets, well under the one-third ceiling: it does not run on borrowed money. Pass
Interest-bearing cash 0.00% Below 33% Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit. Pass
Receivables 41.01% Below 49% Money owed to the company is 41.0% of assets, under the 49% limit. Pass
Revenue purity 57.31% Below 5% 57.3% of revenue comes from non-compliant sources, over the 5% line. Fail

Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.

The Ethical Read

Why It Falls Short, in Plain English

Atlas Lithium does not pass the ethical screen. The binding factor is interest/revenue 57.3%.

Read as at 2026-11-15. It updates when the underlying figures move, and past reads are kept below.

2026-10-25 Does not pass

Atlas Lithium does not pass the ethical screen. The binding factor is interest/revenue 57.3%.

2026-09-24 Clears

Atlas Lithium clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 12%, inside the ~33% line, and almost none of its income is interest, so it passes.

Earlier reads, kept as written. The ethical profile is tracked over time, not overwritten.

Follow this verdict

Get an email when ATLX's ethical verdict changes

Today ATLX does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

How a fair value is estimated: discounted cash flow (DCF).

Price History & Projections

Where our models see it going: no fair-value estimate yet, range not available, dated to the 2026-11-13 screen.

Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.

The Business, in Plain Words
The fundamentals · plain-English read
Forward P/E-3.1x
EPS, trailing-1.55
EPS, forward-0.61
Profit margin0.0%currently unprofitable
Return on equity-108.7%not currently earning a positive return on equity
FCF yield-40.96%
Debt to equity0.20minimal debt: a conservative balance sheet
Current ratio2.43comfortably covers its short-term bills
Beta0.19barely tracks the market's swings
Short interest, float0.07%
52-week range1.86 - 6.72
MoatNONE
Market cap$57M
Employees64

Another profit measure, before interest, tax and non-cash costs: EBITDA.

The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; its business and earnings are exposed to Brazil and to currency swings.

Plain-English interpretation of our own screen data. Analysis, not advice.

Where & How to Trade

ATLX trades on NASDAQ (the company is based in Brazil). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-10 Markdown $1.69 -0.6% Entry 12

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 24%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (1 analysts) rates it none, with a mean price target of $12.

2026-11-03 Markdown $1.70 -10.5% Entry 11

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 10.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 24%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (1 analysts) rates it none, with a mean price target of $12.

2026-10-27 Markdown $1.90 -17.4% Entry 10

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 17.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 24%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (1 analysts) rates it none, with a mean price target of $12.

2026-10-20 Markdown $2.30 +0.4% Entry 9

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 0.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 24%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (1 analysts) rates it none, with a mean price target of $12.

2026-10-13 Markdown $2.29 -22.1% Entry 8

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 22.1% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 24%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (1 analysts) rates it none, with a mean price target of $12.

2026-10-02 Markdown $2.94 +0.0% Entry 7

Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 24%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (1 analysts) rates it none, with a mean price target of $12.

2026-09-24 Markdown · changed $2.94 -6.7% Entry 6

The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 6.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 24%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (1 analysts) rates it none, with a mean price target of $12.

2026-08-22 Accumulation · changed $3.15 +3.6% Entry 5

The framework has shifted from distribution to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 3.6% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 24%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (1 analysts) rates it none, with a mean price target of $12.

2026-07-22 Distribution $3.04 -18.5% Entry 4

Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 18.5% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 24%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (1 analysts) rates it none, with a mean price target of $12.

2026-07-18 Distribution $3.73 +0.0% Entry 3

Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 24%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (1 analysts) rates it none, with a mean price target of $12.

Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.

Latest News · What the Market Is Reading on ATLX

Headlines from third-party outlets, linked for reference: not our reporting, not advice.

Related Securities · Others in ATLX's Space

Screened names in the same industry · explore each on its own page.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $5.96 -43.0% · $571 -43.0%
2 months $4.35 -21.8% · $782 -21.8%
3 months $5.10 -33.3% · $667 -33.3%
6 months $4.49 -24.3% · $757 -24.3%
1 year $4.50 -24.4% · $756 -24.4%
2 years $12.26 -72.3% · $277 -72.3%
3 years $23.49 -85.5% · $145 -85.5%
5 years $10.50 -67.6% · $324 -67.6%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever ATLX does next, these words stay.

Atlas Lithium Corp · ATLX · Markdown · $1.54
Recorded 2026-11-13 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.